RE: Buyers16 Sep 2025 11:01
The new patent filing provides the potential for 20 years of commercial exclusivity for both the diagnostic test and P140 therapy, positioning ImmuPharma as a leader in the next generation of autoimmune disease treatments.
Market Opportunity
Autoimmune diseases affect more than 400 million people worldwide, with a therapeutic market valued at over $100 billion annually. Current treatments remain limited and often unsafe, highlighting a major unmet medical need.
In parallel, the autoimmune diagnostics market represents a rapidly growing opportunity, valued at over $10 billion globally, as healthcare systems increasingly adopt precision diagnostics.
ImmuPharma's novel diagnostic test, designed to identify patients with Type M immune disorder, not only strengthens the value proposition of P140 but also creates an independent commercial opportunity with potential for earlier adoption and partnerships.
With this dual platform - first-in-class therapy plus precision diagnostic - ImmuPharma is pioneering a new era of precision medicine in autoimmune disease, offering accurate diagnosis and a groundbreaking treatment with the potential to achieve full remission.